In this Issue  by unknown
Kidney International (2009) 75          869
http://www.kidney-international.org
© 2009 International Society of Nephrology
in  this  issue
Kidney International (2009) 75, 869. doi:10.1038/ki.2009.88
of circulating mineral aggregates that 
are likely to be critical in the generation 
of vascular calcification in uremia (see 
page 915).
The deposits in  
dense deposit disease
Dense deposit disease (DDD) is a 
rare form of membranoproliferative 
glomerulo nephritis in which the dense 
deposits are located in the mesangium 
and the glomerular basement mem-
branes. On the basis of immunofluo-
rescence studies, it is well known that 
complement factor C3 is present in these 
deposits. Now, the development of laser 
capture microdissection methods, orig-
inally used for mRNA studies but now 
applied to protein analysis, has allowed 
Sethi et al. to identify the components of 
these deposits. Using mass spectrometry, 
the authors found that all of the glomeruli 
contained proteins involved in the alter-
nate pathway of complement activation 
as well as some proteins of the terminal 
complement complex. These glomeruli 
were compared with normal glomeruli 
or those from other glomerular diseases. 
In studies that were ‘nonbiased,’ a large 
number of proteins were detected. How-
ever, simply on the basis of abundance, 
the complement factor proteins were the 
most different between control and DDD 
glomeruli. It is well known that there are 
two fluid-phase regulators of terminal 
complement complex, clusterin and 
Phosphate metabolism 
and chronic  
kidney disease
This issue of Kidney International fea-
tures a series of reviews that discuss 
recent developments in the field of 
phosphate homeostasis in chronic kid-
ney disease. With an introduction by 
editor Marc De Broe (see page 880), 
these papers highlight an emerging 
understanding of the role of phosphate 
in the pathogenesis of the uremic syn-
drome. Prié et al. (see page 882) discuss 
new and exciting discoveries in the reg-
ulation of phosphate-including the role 
of FGF23-and of klotho in the regula-
tion of binding to its receptor, one of 
the major recent discoveries in human 
physiology. Vascular calcification has 
been clearly shown to be one of the most 
toxic side effects of renal failure, which 
predicts dire consequences and has war-
ranted therapies aimed at its prevention; 
a new understanding of the role of phos-
phate in this complication is highlighted 
by Giachelli (see page 890). Silver and 
Naveh-Many review the latest research 
showing how phosphate is involved in 
the function of the parathyroid hor-
mone and vitamin D (see page 898). 
Phosphate binders were one of the first 
targeted therapies for renal failure based 
on a deep understanding of the patho-
physiology of renal disease; Hutchison 
reviews the newest developments in 
this field (see page 906). In addition, 
an original article by Matsui et al. iden-
tifies a role for fetuin in the production 
vitronectin; interestingly, both of these 
proteins were also found in abundance 
in these glomeruli. This article not only 
illuminates the pathogenesis of DDD, but 
also paves the way for the study of other 
glomerular diseases that have deposits of 
unknown nature. See page 952.
Plasma hepcidin  
in renal failure
The study of iron transport has under-
gone a revolution in recent years. Iron 
is absorbed from the intestine by one 
iron transporter and exported into 
the blood by another (ferroportin). 
Regulation of iron exit at the level of 
ferroportin occurs through the inter-
action between this transporter and 
hepcidin, a protein produced by the 
liver that reduces or even blocks iron 
exit by ferroportin. Similarly, hepcidin 
also blocks iron exit from macrophages 
and hepatocytes. Recent studies have 
demonstrated that hepatic synthesis 
of hepcidin increases in inflamma-
tory diseases, which begins to explain 
the so-called anemia of chronic kid-
ney disease. Hepcidin, like other small 
proteins, is filtered and degraded in the 
kidney. Hence, we expect that its level 
is increased in renal failure, which may 
contribute to the anemia of renal failure. 
However, measurement of hepcidin is 
marred by the presence of other forms of 
this protein that may not be functional. 
When Ashby et al. used a new antibody 
generated against the full-length active 
hepcidin, they found that its level was 
elevated in renal failure. This elevation 
did not correlate with an increase in 
interlukin-6, suggesting that it was not 
due to a chronic inflammatory state. 
Although the level of hepcidin cor-
related with anemia, it had a negative 
correlation with erythropoietin levels, 
suggesting that erythropoietin might 
suppress hepcidin. See page 976.
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